Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CARTIGROW is an autologous chondrocyte implantation (ACI) therapy developed by Regrow Biosciences for the treatment of articular cartilage damage and early-stage osteoarthritis. The therapy involves a two-step process: first, a biopsy of healthy cartilage is taken arthroscopically from a non-weight-bearing area of the patient's joint; second, the chondrocytes are isolated and expanded in a GMP-certified facility over approximately four weeks. The resulting high-density cell population is then surgically implanted into the defect site, where the cells produce a new hyaline-like cartilage matrix, restoring joint function and alleviating pain. CARTIGROW received market authorization from the Drug Controller General of India (DCGI) in 2017, making it one of the first approved cell-based therapies in India.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CARTIGROW.